DailyIQ
Last updated1 minute ago

RGEN·Repligen Corporation

$174.89
-14.61 (-7.71%)
Overnight$174.84-0.05 (-0.03%)
High
$194.36
Open
$191.90
Market Cap
10.16B
52W High
$198.87
Low
$174.36
P. Close
$174.89
P/E
244.54
52W Low
$100.99
Fwd P/E
66.10
DailyIQ Est.
$198.27
Inst. Ownership
0.7%
Short Interest
11.55%
Days to Cover
7.1
Technical Score (1D)
50
NEUTRAL
News Sentiment
61
BULLISH
On Oct 6, Repligen Corporation completed its acquisition of BioLife Solutions, adding BioLife’s cell processing tools and services to its portfolio and expanding Repligen’s presence in the cell and gene therapy market. The deal was described as providing a high‑margin consumables business with recurring revenue, and integration plans were already underway to support customers across critical stages of the cell therapy workflow. On Oct 5, the announcement of Repligen’s pending acquisition of BioLife triggered Freshworks’ entry into the S&P SmallCap 600 index, prompting a 4% after‑hours rise in Freshworks shares. The index change was reported to be expected to increase demand from index‑tracking funds, benefiting Freshworks’ liquidity and visibility. Both reports noted that Repligen’s deal with BioLife is still subject to final closing conditions, but the announcement had already moved market sentiment positively for both companies.
LOW TARGET
$145 -17.1%
2 analysts
MEAN TARGET
$190 +8.5%
14 analysts
HIGH TARGET
$225 +28.7%
14 analysts
PRICE RANGE
$145.00 - $225.00
SB / B / H / S / SS
7/17/4/1/1
DAILYIQ EST.
$198.27 (+13.4%)
Bought (1Y)
0 shares
$0
Sold (1Y)
38,419 shares
$7.0M
Loeillot OlivierChief Executive Officer
Option Exercise4,202 shares2026-10-05
Loeillot OlivierChief Executive Officer
Sell4,202 shares2026-10-05
Loeillot OlivierChief Executive Officer
Option Exercise4,202 shares2026-10-05
Loeillot OlivierChief Executive Officer
Sell1,333 shares2026-10-05
Loeillot OlivierChief Executive Officer
Tax Withholding1,248 shares2026-10-02
74/ 100
Bullish
Overall: Bullish
✓Revenue growing year over year
✓Positive net margin
✓Positive operating cash flow
Gross Margin
52.3%
Net Margin
6.6%
Revenue CAGR
26.8%
Current Ratio
8.37x
Debt / Equity
0.26x
Return on Equity
2.3%

EPS

EstBeatMiss
$0.41$0.42$0.44$0.45$0.47Q3'25Q3'26
QtrEstActual+/−
Q3'26$0.46 - -
Q3'25$0.41$0.46+10.9%

Revenue

EstBeatMiss
$186M$193M$200M$207M$214MQ3'25Q3'26
QtrEstActual+/−
Q3'26$211M - -
Q3'25 - $189M -

Market Data

RGEN Stock Snapshot

NEUTRAL50/100
$174.84−$0.05 (0.0%)
Market cap
10.16B
P/E ratio
244.5
Day range
$174.36 – $194.36
News sentiment
61/100 · Bullish
Analyst target
$189.70 (+8.5%)
Consensus
Buy · 30 analysts
52-week range+73.1% off low · -12.1% from high
$100.99$198.87
Price $174.84 DailyIQ Est. $198.27

Neither side has the upper hand on RGEN right now, and the indicator set reflects that. Earnings and guidance carry more weight than macro data at this capitalisation.

Reverse DCF

What growth is priced into RGEN?

RICH

At today's price, Repligen Corporation needs to grow free cash flow about 63.1% a year for the next 10 years to justify its valuation at a 10.64% cost of capital. Over its actual history it has compounded free cash flow at 26.0% a year, so the market is asking for 37.1 percentage points above its own delivered rate. On that basis RGEN looks priced above what its own growth record supports.

Implied FCF growth
63.1%
Historical FCF CAGR
26.0%
Growth gap
+37.1 pts
Verdict
RICH
Discount rate (WACC)
10.64%
Beta
1.15

Behaviour On Record

What RGEN's own history says about today's numbers

Realized volatility (21d)
42.3% 48th pct
Below its peak
-42.6%
vs 200-day average
+32.0%
Up days (1y)
54%

Repligen Corporation is currently running 42.3% annualised volatility over the last 21 sessions. Measured against RGEN's own 13 years of daily returns rather than a market-wide average, that is the 48th percentile — close to its own typical level, against a typical reading of 42.9%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

RGEN is trading -42.6% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -29.7%, and the deepest was -45.5% in 2022. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.

Price sits +32.0% from its 200-day moving average. Against every other day in its history, that gap ranks at the 88th percentile — a wider gap than this stock usually carries. Over the past year RGEN closed higher on 54% of sessions, and it is currently 2 sessions into a rising streak.

On October specifically: over 13 years of records, RGEN finished the month higher 7 of 13 times, with a median return of +2.0% and an average of +2.7%. Its strongest month historically has been July at +8.4% on average, its weakest September at -3.3%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: RGEN has opened more than 2% away from the prior close in 272 of 3,267 sessions (8.3% of the time), with the largest gaps running +28.0% and -10.6%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

All figures computed from 3,268 daily closes between 2013-10-07 and 2026-10-05, split-adjusted, recomputed daily. Percentiles are against RGEN's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of RGEN's sector?

Repligen Corporation sits in the Health Care sector, currently ranked 3rd of 12 GICS sectors by relative-strength rotation score (lagging). Within its narrower Biotechnology industry group, RGEN ranks 9th of 15 tracked industries, lagging.

Sector rank
#3 of 12
Sector state
Lagging
Sector rotation score
36
Industry rank
#9 of 15

Options Market

What is the options market pricing for RGEN?

CallsPuts

For Repligen Corporation's nearest expiry (2026-10-16, 9 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.00), with at-the-money implied volatility around 12.5%. The options market is pricing roughly a ±2.0% move by that expiry — a range of about $190.44–$198.06.

Put/call ratio (2026-10-16)
0.00
ATM implied volatility
12.5%
Total open interest
2,312
Expected move by 2026-10-16
±2.0% ($190.44–$198.06)

Analyst Rating Changes

Are analysts turning bullish or bearish on RGEN?

UBS most recently reiterated its rating on Repligen Corporation to Buy on Sep 9, 2026 with a price target of $225 (from $195). Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.

Latest action
UBS — Buy
90-day upgrades
0
90-day downgrades
0
Net rating momentum
0
DateFirmActionRatingPrice target
Sep 9, 2026UBSMaintainedBuy$195 → $225
Jul 30, 2026Wells FargoMaintainedOverweight$180 → $185
Jul 29, 2026JP MorganMaintainedOverweight$165 → $175
Jul 7, 2026BenchmarkUpgradeHold → Buy$185
Jul 6, 2026Evercore ISI GroupMaintainedOutperform$150 → $160
Jun 3, 2026HSBCMaintainedBuy$170 → $150
May 6, 2026JP MorganMaintainedOverweight$180 → $165
May 6, 2026BarclaysMaintainedOverweight$145 → $160
Apr 20, 2026Canaccord GenuityMaintainedHold$165 → $145
Apr 17, 2026Roth CapitalInitiatedBuy$160
Apr 14, 2026BarclaysMaintainedOverweight$175 → $145
Apr 6, 2026Evercore ISI GroupMaintainedOutperform$170 → $140

News Sentiment Analysis

Sentiment gathered from recent headlines

61/100
Strong NegativeNeutralStrong Positive
MODERATELY BULLISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
On October 5, 2026, Repligen CEO Olivier Loeillot sold 5,535 shares for $1,036,654, reducing his holdings to 45,788 shares. The transaction was reported in a Form 4 filing with the SEC. The sale may signal a lack of confidence in the company’s near‑term prospects, potentially impacting investor sentiment.
What did this article say?
Repligen (RGEN) announced on October 6 that it had closed its acquisition of BioLife Solutions (BLFS). Shareholders of BioLife received $11.25 in cash and 0.1442 shares of RGEN common stock per share, with cash used to replace fractional shares. The deal is expected to broaden RGEN’s global footprint and enhance its cell‑therapy portfolio, with detailed financial impact to be disclosed in the upcoming Q3 earnings call. RGEN shares fell 3% in early trading following the announcement.
What did this article say?
Repligen Corporation completed its acquisition of BioLife Solutions on October 6, 2026, adding BioLife’s cell processing tools and services to its portfolio. The deal enhances Repligen’s presence in the growing cell and gene therapy market, providing a high‑margin consumables business with recurring revenue. Integration plans were already underway, positioning the combined entity to support customers across critical stages of the cell therapy workflow.
What did this article say?
Repligen Corporation announced that it will acquire BioLife Solutions, a move that is expected to close soon pending final conditions. The acquisition positions RGEN to expand its product portfolio and strengthen its market presence in the biopharmaceutical sector. The deal is anticipated to generate additional revenue streams and enhance RGEN’s competitive standing. Investors viewed the announcement favorably, reflecting confidence in the strategic fit and potential upside. The transaction is expected to be completed before the end of the fiscal year.
What did this article say?
RGEN closed up 2% on September 29 after reporting a strong second‑quarter 2026 earnings beat and raising its full‑year guidance. The company also announced an expansion into cell therapy, adding a new revenue stream. These developments reinforced investor confidence and pushed the stock to a fresh 52‑week high.
What did this article say?
Repligen Corporation (RGEN) published a slide deck in conjunction with the Wells Fargo 21st Annual Healthcare Conference, providing no new financial or operational data.
What did this article say?
Repligen’s adjusted operating margin has fallen 16.2 percentage points over five years, raising concerns about rising costs and shrinking profitability. Despite recent stock gains, analysts highlight a deteriorating expense base that could limit future growth. The report cautions investors that the company’s momentum may not sustain without a turnaround in margin performance.
What did this article say?
Repligen Corporation (RGEN) participated in the Wells Fargo 21st Annual Healthcare Conference, where CEO Olivier Loeillot and CFO Jason Garland discussed the company’s organic growth trajectory and strategic priorities. The executives emphasized a 13% growth rate in the second quarter and outlined initiatives aimed at sustaining momentum. While no new financial guidance was released, the presentation reinforced RGEN’s focus on expanding its product portfolio and strengthening client relationships.
What did this article say?
UBS analyst Dan Leonard has upgraded Repligen to a Buy and lifted the price target from $195 to $225, reflecting confidence in the company’s growth prospects. The upgrade signals a bullish view on Repligen’s product pipeline and market positioning.
What did this article say?
UBS has lifted its price target for Repligen (RGEN) to $225 from $195 while maintaining a buy rating, reflecting confidence in the company’s growth prospects. The upgrade follows a review of RGEN’s recent product pipeline and expanding contract portfolio, suggesting stronger revenue traction. Analysts highlight the company’s focus on bioprocessing solutions and its strategic positioning in the growing biologics market as key drivers for the target increase.

Technical Analysis

Real-time indicators across multiple timeframes

50
NEUTRAL
Technical indicators reflect the latest computed signal mix for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
1 tracked managers · $58.27M combined position · 0 adding, 0 trimming, 1 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
Citadel Advisors LLC• Hold427,1090.74%$58.27M2026-09-02
Q2 2026 flow:427.1K sh bought ($58.27M)0 sh sold ($0)net +427.1K sh (+$58.27M)
Congressional Trading Activity
4 disclosed trades · ~$56.5K est. traded value · 2 buys, 2 sells
MemberChamberStateTypeAmountTradedFiled
Lisa McClainHouseMI09▲ Buy$1K - $15K2025-10-302025-11-21
Lisa McClainHouseMI09▼ Sell$1K - $15K2025-06-172025-08-13
Lisa McClainHouseMI09▲ Buy$1K - $15K2025-06-112025-08-13
Jefferson ShreveHouseIN06▼ Sell$15K - $50K2025-04-072025-05-08